NVCR NovoCure Limited Stock Quote

NVCR [NASD]

Healthcare | Medical Instruments & Supplies | USA

Index	-	P/E	2350.71	EPS (ttm)	0.07	Insider Own	1.60%	Shs Outstand	101.23M	Perf Week	-2.22%
Market Cap	17.02B	Forward P/E	384.46	EPS next Y	0.43	Insider Trans	-26.63%	Shs Float	86.71M	Perf Month	-3.61%
Income	7.90M	PEG	-	EPS next Q	0.10	Inst Own	83.80%	Short Float	6.19%	Perf Quarter	32.95%
Sales	449.60M	P/S	37.86	EPS this Y	89.30%	Inst Trans	15.41%	Short Ratio	4.90	Perf Half Y	145.56%
Book/sh	3.03	P/B	54.31	EPS next Y	79.83%	ROA	3.90%	Target Price	136.00	Perf Year	89.14%
Cash/sh	2.27	P/C	72.59	EPS next 5Y	-	ROE	7.40%	52W Range	53.40 - 182.74	Perf YTD	-4.91%
Dividend	-	P/FCF	422.40	EPS past 5Y	40.20%	ROI	0.20%	52W High	-9.95%	Beta	1.04
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	86.70%	Gross Margin	77.10%	52W Low	208.15%	ATR	8.08
Employees	782	Current Ratio	4.00	Sales Q/Q	44.10%	Oper. Margin	4.10%	RSI (14)	49.22	Volatility	4.37% 4.53%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	376.30%	Profit Margin	4.30%	Rel Volume	0.38	Prev Close	167.19
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Oct 29 BMO	Payout	0.00%	Avg Volume	1.10M	Price	164.55
Recom	2.80	SMA20	-2.96%	SMA50	7.21%	SMA200	63.28%	Volume	416,570	Change	-1.58%

Jan-25-21

Reiterated

Piper Sandler

Overweight

$140 → $225

Sep-23-20

Initiated

Northland Capital

Outperform

$200

Sep-18-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$116

Sep-17-20

Downgrade

Truist

Buy → Hold

$108

Jun-01-20

Resumed

Oppenheimer

Perform

May-01-20

Downgrade

Oppenheimer

Outperform → Perform

Apr-09-20

Downgrade

Evercore ISI

In-line → Underperform

$58

Mar-05-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$85 → $90

Jan-02-20

Downgrade

Evercore ISI

Outperform → In-line

$84 → $90

Jul-29-19

Upgrade

SunTrust

Hold → Buy

Jul-26-19

Downgrade

Wedbush

Outperform → Neutral

$57 → $80

Jul-26-19

Downgrade

JP Morgan

Overweight → Neutral

$61 → $79

Mar-20-19

Initiated

SunTrust

Hold

Nov-02-18

Downgrade

Wells Fargo

Outperform → Market Perform

Jul-16-18

Initiated

Evercore ISI

Outperform

$46

Apr-18-18

Reiterated

Mizuho

Buy

$28 → $32

Feb-23-18

Reiterated

Mizuho

Buy

$25 → $28

May-24-17

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-29-16

Reiterated

Wedbush

Outperform

$30 → $20

Jan-19-16

Initiated

Barclays

Underweight

$16

Jan-24-21 09:45AM	Investors Take Note: This Biotech Stock Has Multiple Readouts in 2021 Motley Fool
Jan-15-21 08:34AM	Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock? Zacks -6.37%
Jan-11-21 06:00AM	Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update Business Wire
Jan-04-21 12:43PM	NovoCure Could Weaken Further in the Days Ahead TheStreet.com -6.77%
Dec-23-20 07:30AM	Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference Business Wire
Dec-19-20 09:32PM	Is NVCR A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-14-20 01:00AM	Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Dec-10-20 07:30AM	First Patient Enrolled in Novocures Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma Business Wire
Dec-07-20 12:15PM	Dow Jones Falls Amid Stimulus News, But Apple Holds Above New Buy Point; Tesla Hits Record High Investor's Business Daily
03:06AM	Is NovoCure Limited's (NASDAQ:NVCR) Recent Stock Performance Influenced By Its Fundamentals In Any Way? Simply Wall St.
Dec-04-20 05:04PM	IBD Stock Of The Day Breaks Out To A Record High As 2021 Catalysts Loom Investor's Business Daily +9.21%
04:12PM	Stock Market Closes With Record Highs But These Stocks Can't Keep Up Investor's Business Daily
03:04PM	Dow Jones, S&P 500, Nasdaq Score Fresh Highs; Small Caps Surge, Snowflake Rips Higher, DocuSign Fades Investor's Business Daily
10:14AM	Novocure Blasts Higher Investor's Business Daily Video
Dec-01-20 07:00AM	Is Inovio Pharmaceuticals a Buy? Motley Fool
Nov-25-20 07:30AM	Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference Business Wire
Nov-24-20 03:40PM	Why Novocure Stock Sank Today Motley Fool -11.16%
11:41AM	Novocure Has Ugly Retreat Investor's Business Daily Video
Nov-23-20 04:51PM	Dow Jones Futures: Latest Bitcoin Play PayPal In Buy Zone As Tesla, Nio, Xpeng Fly; Apple Stock Breaks Support Investor's Business Daily
Nov-21-20 08:00AM	AMD, Twilio, Novocure Among 5 Stocks Flashing Multiple Buy Signals Investor's Business Daily
Nov-20-20 11:34AM	Novocure Flashes Several Buy Signals Investor's Business Daily Video +5.67%
Nov-19-20 05:30PM	Dow Jones Futures: AMD, Twilio Flash Early Entries, Tesla, Nio Keep Rising In Stock Market Rally; Workday Earnings Top Investor's Business Daily
04:51PM	Why This IBD Stock Of The Day Is A 2021 Story But It's Actionable Now Investor's Business Daily
08:00AM	Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting Business Wire
Nov-14-20 05:58AM	3 Revolutionary Stocks That Can Make You Rich Motley Fool
Nov-11-20 07:30AM	Novocure Receives CE Mark for NovoTTF-100L System Business Wire
Nov-10-20 07:30AM	Novocure Announces Agenda for Virtual Research and Development Day Business Wire -5.56%
Nov-09-20 07:30AM	Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks Business Wire
Nov-05-20 04:00PM	Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement Business Wire
03:40PM	Dow Jones Aims At 2,000-Point Weekly Gain; These Top Stocks Rumble Past New Buy Points Investor's Business Daily
Nov-04-20 03:25PM	Growing Novocure Sees Composite Rating Improve To 96 Investor's Business Daily +7.13%
11:26AM	How to Play NovoCure Stock Right Now TheStreet.com
Nov-02-20 08:52PM	Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement Business Wire -8.14%
07:04AM	Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes Business Wire
Oct-30-20 12:04AM	NovoCure (NVCR) Q3 2020 Earnings Call Transcript Motley Fool
Oct-29-20 06:00AM	Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update Business Wire +6.83%
06:00AM	Novocure Ltd. to Host Earnings Call ACCESSWIRE
06:00AM	Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research Business Wire
Oct-28-20 12:26PM	Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More Zacks
06:15AM	Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release? Motley Fool
Oct-23-20 11:50AM	Will NovoCure's (NASDAQ:NVCR) Growth In ROCE Persist? Simply Wall St.
Oct-09-20 08:23AM	3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic Zacks +7.30%
Oct-07-20 12:11PM	Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day Zacks +6.43%
Oct-05-20 03:27PM	NovoCure Surges to New Highs: Here's the Technical Road Ahead TheStreet.com
Oct-02-20 11:30AM	Is NovoCure (NVCR) Outperforming Other Medical Stocks This Year? Zacks
08:56AM	Novocure to Report Third Quarter 2020 Financial Results Business Wire
Sep-29-20 07:30AM	Novocure to Host Virtual Research & Development Day Business Wire
Sep-28-20 08:43PM	Hedge Funds Are Done Buying NovoCure Limited (NVCR) Insider Monkey
Sep-25-20 04:00PM	Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community Business Wire
Sep-24-20 12:41PM	Novocure Steady After Breakout Investor's Business Daily Video
Sep-23-20 11:25AM	Here's What We Think About NovoCure's (NASDAQ:NVCR) CEO Pay Simply Wall St.
Sep-09-20 03:12PM	Dow Jones Retraces A Third Of Its 1,735-Point Loss; Will These Growth Stocks Recover? Investor's Business Daily
Sep-04-20 07:30AM	Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference Business Wire
Aug-29-20 08:00AM	Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise Investor's Business Daily
Aug-24-20 03:29PM	NovoCure (NASDAQ:NVCR) Shareholders Have Enjoyed An Impressive 290% Share Price Gain Simply Wall St.
Aug-13-20 11:37AM	Understanding NovoCure's Unusual Options Activity Benzinga
08:30AM	Novocure Announces Expansion of Its Executive Leadership Team Business Wire
Jul-30-20 09:01PM	NovoCure (NVCR) Q2 2020 Earnings Call Transcript Motley Fool +12.01%
06:00AM	Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update Business Wire
Jul-28-20 07:30AM	Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program Business Wire
Jul-24-20 09:37PM	3 Great Healthcare Stocks to Watch Motley Fool
Jul-23-20 12:33PM	NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards? Zacks
12:00PM	What Type Of Shareholders Make Up NovoCure Limited's (NASDAQ:NVCR) Share Registry? Simply Wall St.
Jul-22-20 07:30AM	First Patient Enrolled in Novocures EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays Business Wire +5.33%
Jul-15-20 04:38PM	Dow Jones Giant Merck Inks A New Deal In Lung Cancer And Shares Pop Investor's Business Daily +9.46%
09:10AM	Merck, Novocure Team Up On Lung Cancer Treatment; Trial Set For 2H20 SmarterAnalyst
07:30AM	Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer Business Wire
Jul-12-20 08:54PM	Did Hedge Funds Make The Right Call On NovoCure Limited (NVCR) ? Insider Monkey
Jul-08-20 07:30AM	Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua Business Wire
06:00AM	The 2 Little-Known Growth Stocks I Bought Last Week Motley Fool
Jul-07-20 07:30AM	Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer Business Wire -5.22%
Jul-01-20 07:30AM	Novocure to Report Second Quarter 2020 Financial Results Business Wire
Jun-18-20 12:02PM	Has NovoCure Limited (NASDAQ:NVCR) Stock's Recent Performance Got Anything to Do With Its Financial Health? Simply Wall St.
Jun-08-20 01:07AM	Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR) Insider Monkey
Jun-02-20 07:30AM	Novocure Announces Launch of MyLink to Enable Patient-Guided, Remote Download of Optune® Usage Data Business Wire
May-13-20 10:10AM	China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Business Wire
May-05-20 11:30PM	Edited Transcript of NVCR earnings conference call or presentation 30-Apr-20 12:00pm GMT Thomson Reuters StreetEvents
May-04-20 10:21AM	Is NovoCure Limited (NASDAQ:NVCR) Potentially Undervalued? Simply Wall St.
May-02-20 11:30AM	NovoCure Limited (NVCR) Q1 2020 Earnings Call Transcript Motley Fool
Apr-30-20 04:05PM	Highly Rated Cancer Play Tumbles As Key Studies Delayed Amid Outbreak Investor's Business Daily -10.52%
07:30AM	NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates Zacks
06:00AM	Novocure Reports First Quarter 2020 Financial Results and Provides Company Update Business Wire
Apr-27-20 07:30AM	Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I Business Wire
Apr-23-20 12:32PM	NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-07-20 03:07PM	Is NovoCure (NASDAQ:NVCR) A Risky Investment? Simply Wall St. -6.60%
09:00AM	Medical Services Outlook Bright Amid Coronavirus Crisis Zacks
Apr-03-20 07:30AM	Novocure Provides Business Update Related to COVID-19 Business Wire
Mar-23-20 12:24AM	Hedge Funds Started Selling NovoCure Limited (NVCR) Before The Coronavirus Insider Monkey
Mar-20-20 09:16AM	German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany Business Wire -6.68%
Mar-19-20 07:30AM	Novocure Announces Optune Lua as the Brand Name for the NovoTTF-100L System Business Wire +9.50%
Mar-12-20 07:30AM	Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy Business Wire
Mar-10-20 03:18AM	Edited Transcript of NVCR earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-27-20 07:30AM	NovoCure (NVCR) Q4 Earnings and Revenues Beat Estimates Zacks
06:00AM	Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update Business Wire
Feb-20-20 12:31PM	NovoCure (NVCR) Earnings Expected to Grow: Should You Buy? Zacks
Feb-11-20 08:54AM	Is NovoCure Limited's (NASDAQ:NVCR) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-05-20 09:15AM	NASDAQ Reaches New Closing High as Rebound Continues Zacks
Feb-04-20 02:56PM	Expand Your Portfolio with this First Profit Stock Screener Zacks
Jan-29-20 09:15AM	Relief Rally Snaps the Dow's 5-Day Losing Skid Zacks
Jan-23-20 07:24AM	The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment Benzinga

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Longsworth Todd Christopher	General Counsel	Jan 15	Option Exercise	14.37	36,396	523,011	123,474	Jan 19 05:00 PM
Longsworth Todd Christopher	General Counsel	Jan 15	Sale	172.48	63,814	11,006,647	59,660	Jan 19 05:00 PM
Benaim Ely	Chief Medical Officer	Dec 21	Option Exercise	56.93	2,484	141,406	31,189	Dec 22 06:39 PM
Benaim Ely	Chief Medical Officer	Dec 21	Sale	156.71	2,484	389,268	29,356	Dec 22 06:39 PM
Danziger Asaf	Chief Executive Officer	Dec 18	Option Exercise	22.00	207,910	4,574,020	301,587	Dec 22 06:37 PM
HILLEMAN JERYL L	Director	Dec 18	Sale	166.40	2,500	416,000	3,400	Dec 22 06:38 PM
Danziger Asaf	Chief Executive Officer	Dec 18	Sale	157.39	207,910	32,722,764	197,632	Dec 22 06:37 PM
Cordova Ashley	Chief Financial Officer	Nov 02	Sale	117.41	230	27,005	26,212	Nov 03 04:23 PM
Shah Pritesh	Chief Commercial Officer	Oct 29	Option Exercise	10.13	30,468	308,588	89,758	Oct 30 04:08 PM
Weinberg Uri	Chief Science Officer	Sep 25	Option Exercise	9.62	15,250	146,750	36,347	Sep 28 06:13 PM
Weinberg Uri	Chief Science Officer	Sep 25	Sale	103.35	15,250	1,576,088	27,597	Sep 28 06:13 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 18	Option Exercise	7.48	8,262	61,800	150,869	Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 18	Sale	109.21	8,262	902,294	142,607	Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 17	Option Exercise	7.48	12,500	93,500	155,107	Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 17	Sale	108.60	12,500	1,357,556	142,607	Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 16	Option Exercise	7.29	22,012	160,369	155,107	Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 16	Sale	107.35	22,012	2,363,014	142,607	Sep 18 04:37 PM
LEUNG GABRIEL	Director	Sep 15	Option Exercise	7.48	9,565	71,546	79,437	Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 15	Option Exercise	7.37	50,868	374,868	155,975	Sep 16 05:24 PM
Danziger Asaf	Chief Executive Officer	Sep 15	Option Exercise	22.00	103,000	2,266,000	300,632	Sep 17 04:32 PM
Danziger Asaf	Chief Executive Officer	Sep 15	Sale	99.00	103,000	10,197,000	197,632	Sep 17 04:32 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 15	Sale	103.27	50,868	5,253,018	142,607	Sep 16 05:24 PM
LEUNG GABRIEL	Director	Sep 15	Sale	100.00	9,565	956,500	72,045	Sep 16 05:27 PM
LEUNG GABRIEL	Director	Sep 14	Option Exercise	7.48	10,000	74,800	82,045	Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 14	Option Exercise	7.03	25,000	175,750	155,107	Sep 16 05:24 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 14	Sale	98.01	25,000	2,450,213	142,607	Sep 16 05:24 PM
LEUNG GABRIEL	Director	Sep 14	Sale	95.00	10,000	950,000	72,045	Sep 16 05:27 PM
LEUNG GABRIEL	Director	Sep 10	Option Exercise	7.48	10,000	74,800	82,045	Sep 11 04:15 PM
LEUNG GABRIEL	Director	Sep 10	Sale	90.00	10,000	900,000	72,045	Sep 11 04:15 PM
LEUNG GABRIEL	Director	Sep 09	Option Exercise	7.03	9,114	64,071	81,159	Sep 11 04:15 PM
LEUNG GABRIEL	Director	Sep 09	Sale	85.40	9,114	778,293	72,045	Sep 11 04:15 PM
Shah Pritesh	Chief Commercial Officer	Sep 09	Sale	85.41	28,321	2,418,881	70,465	Sep 11 04:19 PM
LEUNG GABRIEL	Director	Sep 02	Option Exercise	7.03	100	703	72,145	Sep 04 04:17 PM
LEUNG GABRIEL	Director	Sep 02	Sale	85.00	100	8,500	72,045	Sep 04 04:17 PM
LEUNG GABRIEL	Director	Aug 25	Option Exercise	7.03	7,112	49,997	79,157	Aug 27 04:13 PM
LEUNG GABRIEL	Director	Aug 25	Sale	80.13	7,112	569,892	72,045	Aug 27 04:13 PM
Shah Pritesh	Chief Commercial Officer	Aug 04	Sale	76.81	2,048	157,307	101,018	Aug 05 04:13 PM
Shah Pritesh	Chief Commercial Officer	Aug 03	Sale	76.41	1,669	127,522	103,066	Aug 05 04:13 PM
Benaim Ely	Chief Medical Officer	Aug 03	Sale	76.06	660	50,200	29,356	Aug 05 04:11 PM
Shah Pritesh	Chief Commercial Officer	Jul 31	Option Exercise	76.17	3,717	283,124	104,735	Aug 03 05:39 PM
Benaim Ely	Chief Medical Officer	Jul 31	Sale	76.39	341	26,048	30,016	Aug 03 05:53 PM
DOYLE WILLIAM F	Executive Chairman	Jul 31	Sale	76.39	896	68,444	649,062	Aug 03 05:51 PM
LEUNG GABRIEL	Director	Jul 30	Option Exercise	7.03	7,112	49,997	79,157	Aug 03 05:45 PM
LEUNG GABRIEL	Director	Jul 30	Sale	75.00	7,112	533,400	72,045	Aug 03 05:45 PM
LEUNG GABRIEL	Director	Jul 22	Option Exercise	7.03	9,500	66,785	81,545	Jul 23 07:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 22	Option Exercise	18.40	42,972	790,640	251,639	Jul 23 07:43 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 22	Sale	67.02	42,972	2,879,966	220,867	Jul 23 07:43 PM
LEUNG GABRIEL	Director	Jul 22	Sale	67.03	9,500	636,797	72,045	Jul 23 07:32 PM
LEUNG GABRIEL	Director	Jul 21	Option Exercise	7.03	500	3,515	72,545	Jul 23 07:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 21	Option Exercise	20.27	3,321	67,332	223,888	Jul 23 07:43 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 21	Sale	65.06	3,321	216,072	220,867	Jul 23 07:43 PM
LEUNG GABRIEL	Director	Jul 21	Sale	65.07	500	32,537	72,045	Jul 23 07:32 PM
Benaim Ely	Chief Medical Officer	May 12	Sale	64.78	2,595	168,104	12,616	May 14 04:14 PM
DOYLE WILLIAM F	Executive Chairman	May 11	Sale	63.73	31,332	1,996,726	649,958	May 12 04:13 PM
Benaim Ely	Chief Medical Officer	May 11	Sale	63.73	1,611	102,666	15,211	May 12 04:22 PM
DOYLE WILLIAM F	Executive Chairman	May 08	Option Exercise	63.84	58,767	3,751,685	713,193	May 11 04:17 PM
Benaim Ely	Chief Medical Officer	May 08	Option Exercise	63.84	4,206	268,511	16,822	May 12 04:22 PM
Weinberg Uri	Chief Science Officer	May 08	Option Exercise	63.84	1,402	89,504	25,629	May 11 04:22 PM
DOYLE WILLIAM F	Executive Chairman	May 08	Sale	63.50	31,903	2,025,872	681,290	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 07	Option Exercise	64.77	58,768	3,806,403	685,419	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 07	Sale	64.74	30,993	2,006,518	654,426	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 06	Option Exercise	64.15	58,768	3,769,967	626,651	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 06	Sale	64.27	29,881	1,920,452	567,883	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 05	Option Exercise	61.40	58,768	3,608,355	628,047	May 07 04:41 PM
Shah Pritesh	Chief Commercial Officer	May 05	Sale	62.20	1,149	71,468	100,693	May 07 04:48 PM
DOYLE WILLIAM F	Executive Chairman	May 05	Sale	62.47	30,283	1,891,718	597,764	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 04	Option Exercise	60.48	58,768	3,554,289	569,279	May 06 05:52 PM
Shah Pritesh	Chief Commercial Officer	May 04	Sale	60.08	1,184	71,134	101,842	May 05 04:32 PM
Shah Pritesh	Chief Commercial Officer	May 01	Option Exercise	65.80	2,333	153,511	103,026	May 05 04:32 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 14	Option Exercise	7.15	35,745	255,577	256,612	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 14	Sale	71.00	27,519	1,953,970	220,867	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 13	Option Exercise	7.15	22,755	162,698	243,622	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 13	Sale	69.32	30,981	2,147,594	220,867	Apr 15 05:03 PM
Shah Pritesh	Chief Commercial Officer	Mar 06	Option Exercise	7.48	17,500	130,900	103,938	Mar 10 04:20 PM
DOYLE WILLIAM F	Executive Chairman	Mar 06	Sale	69.53	4,320	300,387	510,511	Mar 10 04:18 PM
Longsworth Todd Christopher	General Counsel	Mar 06	Sale	69.53	2,499	173,765	86,753	Mar 10 04:15 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 06	Sale	69.53	3,123	217,155	140,386	Mar 10 04:13 PM
Ambrogi Michael J.	Chief Operating Officer	Mar 06	Sale	69.53	2,274	158,120	220,867	Mar 10 04:22 PM
Shah Pritesh	Chief Commercial Officer	Mar 06	Sale	66.76	6,151	410,622	86,438	Mar 10 04:20 PM
Shah Pritesh	Chief Commercial Officer	Mar 02	Sale	72.97	1,485	108,360	67,721	Mar 05 04:47 PM
Shah Pritesh	Chief Commercial Officer	Feb 28	Sale	72.22	1,601	115,616	69,206	Mar 02 05:22 PM
Longsworth Todd Christopher	General Counsel	Feb 28	Sale	72.22	2,643	190,864	70,032	Mar 02 05:11 PM
DOYLE WILLIAM F	Executive Chairman	Feb 28	Sale	72.22	3,893	281,133	514,831	Mar 02 05:13 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 28	Sale	72.22	2,673	193,031	208,726	Mar 02 05:17 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 27	Option Exercise	79.45	6,173	490,445	211,399	Mar 02 05:17 PM
Danziger Asaf	Chief Executive Officer	Feb 27	Option Exercise	79.45	9,259	735,628	197,348	Mar 02 05:15 PM
DOYLE WILLIAM F	Executive Chairman	Feb 27	Option Exercise	79.45	9,259	735,628	518,724	Mar 02 05:13 PM
Longsworth Todd Christopher	General Counsel	Feb 27	Option Exercise	79.45	5,556	441,424	72,675	Mar 02 05:11 PM
Shah Pritesh	Chief Commercial Officer	Feb 27	Option Exercise	79.45	3,086	245,183	70,807	Mar 02 05:22 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 27	Option Exercise	0.00	7,716	0	119,484	Mar 02 05:18 PM
Shah Pritesh	Chief Commercial Officer	Feb 26	Sale	79.39	7,932	629,725	67,721	Feb 28 04:41 PM
Shah Pritesh	Chief Commercial Officer	Feb 25	Sale	81.16	5,067	411,217	75,653	Feb 28 04:41 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 25	Sale	81.16	11,647	945,224	205,226	Feb 26 05:10 PM
Longsworth Todd Christopher	General Counsel	Feb 25	Sale	81.16	8,482	688,365	67,119	Feb 26 05:14 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 25	Sale	81.16	18,908	1,534,498	111,768	Feb 26 05:17 PM
Danziger Asaf	Chief Executive Officer	Feb 24	Option Exercise	88.26	53,333	4,707,171	188,089	Feb 26 05:19 PM
Shah Pritesh	Chief Commercial Officer	Feb 24	Option Exercise	88.26	12,999	1,147,292	80,720	Feb 26 05:18 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 24	Option Exercise	88.26	43,333	3,824,571	130,676	Feb 26 05:17 PM
Longsworth Todd Christopher	General Counsel	Feb 24	Option Exercise	88.26	21,666	1,912,241	75,601	Feb 26 05:14 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 24	Option Exercise	88.26	31,199	2,753,624	216,873	Feb 26 05:10 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience